benzo(c)fluorene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9150 |
| CHEBI ID | 82403 |
| MeSH ID | M0123111 |
| Synonym |
|---|
| 205-12-9 |
| 3,4-benzofluorene |
| nsc89264 |
| nsc-89264 |
| benzo[c]fluorene |
| 7h-benzo[c]fluorene |
| 7h-benzo(c)fluorene |
| einecs 205-908-2 |
| nsc 89264 |
| benzo(c)fluorene (van) |
| brn 2046366 |
| benzo(c)fluorene |
| C19344 |
| AKOS024329406 |
| 30777-20-9 |
| unii-px3702dw3a |
| 4-05-00-02473 (beilstein handbook reference) |
| px3702dw3a , |
| FT-0631867 |
| CHEBI:82403 |
| 7h-benzo[c]fluorene 10 microg/ml in cyclohexane |
| DTXSID30874039 |
| benzo(c)fluorene [iarc] |
| Q25352041 |
| mfcd00215929 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The selective formation of the benzo[c]fluorene:DNA adduct with coal tar contaminated soils indicates that the in vivo systemic bioavailability and/or metabolism of benzo[c]fluorene is relatively high when compared to other DNA adducting hydrocarbons within coal tar." | ( Comparative analysis of PAH:DNA adducts formed in lung of mice exposed to neat coal tar and soils contaminated with coal tar. Koganti, A; Ma, BL; Singh, R; Weyand, EH, 2001) | 0.31 |
| Class | Description |
|---|---|
| carbotetracyclic compound | A carbopolyclic compound comprising of four carbocyclic rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||